EGFR and cancer: The combination of dasatinib with EGFR inhibitors is under investigation in other cancer types, as the ongoing Phase I clinical trial NCT00996723 evaluating the combination of the vandetanib and dasatinib during and after radiation therapy in diagnosed diffuse intrinsic pontine glioma (Table 3).